Paulo Fontoura

13.2k total citations · 4 hit papers
91 papers, 3.6k citations indexed

About

Paulo Fontoura is a scholar working on Molecular Biology, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Paulo Fontoura has authored 91 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 24 papers in Physiology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Paulo Fontoura's work include Alzheimer's disease research and treatments (24 papers), Multiple Sclerosis Research Studies (12 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Paulo Fontoura is often cited by papers focused on Alzheimer's disease research and treatments (24 papers), Multiple Sclerosis Research Studies (12 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Paulo Fontoura collaborates with scholars based in Switzerland, United States and United Kingdom. Paulo Fontoura's co-authors include Lawrence Steinman, Hideki Garren, Peggy P. Ho, Raymond A. Sobel, Lowen Y. Lee, Gregory Klein, Paul Delmar, Luca Santarelli, Carsten Hofmann and Omar Khwaja and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Paulo Fontoura

86 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

2017 411 citations Tania Nikolcheva, Carsten Hofmann et al. profile →
Risdiplam in Type 1 Spinal Muscular Atrophy

2021 260 citations Eugenio Mercuri, Ksenija Gorni et al. profile →
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

2021 160 citations Claudio Bruno, Ksenija Gorni et al. profile →
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease

2024 56 citations Gennaro Pagano, Tanya Simuni et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paulo Fontoura Switzerland	26	1.1k	727	726	538	448	91	3.6k
Cinzia Dello Russo Italy	32	1.2k 1.1×	287 0.4×	877 1.2×	644 1.2×	183 0.4×	77	3.5k
Bob Olsson Sweden	38	1.7k 1.5×	621 0.9×	1.7k 2.4×	451 0.8×	337 0.8×	91	5.4k
Chiara Fenoglio Italy	41	2.1k 1.9×	454 0.6×	1.9k 2.6×	924 1.7×	206 0.5×	172	5.7k
Pentti J. Tienari Finland	37	1.9k 1.7×	969 1.3×	1.7k 2.3×	764 1.4×	337 0.8×	143	5.5k
María Pascual Spain	38	1.4k 1.2×	618 0.9×	591 0.8×	463 0.9×	115 0.3×	86	4.9k
Fabrizio Giuliani Canada	29	1.1k 1.0×	1.4k 1.9×	423 0.6×	1.2k 2.3×	102 0.2×	69	4.6k
Jeffrey P. Greenfield United States	34	976 0.9×	277 0.4×	1.4k 2.0×	153 0.3×	714 1.6×	143	4.7k
Annachiara Cagnin Italy	23	749 0.7×	189 0.3×	1.1k 1.5×	206 0.4×	309 0.7×	59	3.5k
Markus Kipp Germany	45	2.2k 1.9×	2.0k 2.8×	571 0.8×	1.3k 2.4×	175 0.4×	160	6.7k
Karen Gertz Germany	37	1.4k 1.3×	221 0.3×	520 0.7×	443 0.8×	125 0.3×	80	4.7k

Countries citing papers authored by Paulo Fontoura

Since Specialization

Citations

This map shows the geographic impact of Paulo Fontoura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paulo Fontoura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paulo Fontoura more than expected).

Fields of papers citing papers by Paulo Fontoura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paulo Fontoura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paulo Fontoura. The network helps show where Paulo Fontoura may publish in the future.

Co-authorship network of co-authors of Paulo Fontoura

This figure shows the co-authorship network connecting the top 25 collaborators of Paulo Fontoura. A scholar is included among the top collaborators of Paulo Fontoura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paulo Fontoura. Paulo Fontoura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boada, Merçé, Szofia Bullain, Tobias Bittner, et al.. (2024). Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). Journal of Alzheimer s Disease. 103(2). 528–541.

Pagano, Gennaro, Annabelle Monnet, Benjamin Ribba, et al.. (2024). Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial. Nature Medicine. 30(12). 3669–3675. 14 indexed citations

Chiriboga, Claudia A., Claudio Bruno, Tina Duong, et al.. (2024). JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of Neurology. 271(8). 4871–4884. 8 indexed citations

Bullain, Szofia, Paul Delmar, Gregory Klein, et al.. (2023). Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer’s disease. Alzheimer s & Dementia. 19(S7). 3 indexed citations

Lane, Christopher, Szofia Bullain, Angeliki Thanasopoulou, et al.. (2022). Baseline Characteristics of the GRADUATE Studies: Phase III Randomized, Placebo-Controlled Studies Investigating Subcutaneous Gantenerumab in Participants with Early Alzheimer’s Disease (P16-3.005). Neurology. 98(18_supplement). 2 indexed citations

Umbricht, Daniel, Markus Niggli, Patricia Sanwald Ducray, et al.. (2020). Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder. The Journal of Clinical Psychiatry. 81(4). 31 indexed citations

Bolognani, Federico, Marta del Valle Rubido, Lisa Squassante, et al.. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine. 11(491). 75 indexed citations

Klein, Gregory, Paul Delmar, Sunita Rehal, et al.. (2019). Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies (S9.007). Neurology. 92(15_supplement).

Youssef, Eriene, Elizabeth Berry‐Kravis, Christian Czech, et al.. (2017). Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. Neuropsychopharmacology. 43(3). 503–512. 93 indexed citations

10.

Arnold, Douglas L., Amit Bar‐Or, Giancarlo Comi, et al.. (2016). Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002). Neurology. 86(16_supplement). 1 indexed citations

11.

Traboulsee, Anthony, Douglas L. Arnold, Amit Bar‐Or, et al.. (2016). Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004). Neurology. 86(16_supplement). 12 indexed citations

12.

Quiroz, Jorge A., Dennis Deptula, Ludger Banken, et al.. (2016). Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression. JAMA Psychiatry. 73(7). 675–675. 103 indexed citations

13.

Rubido, Marta del Valle, Eric Hollander, James T. McCracken, et al.. (2016). A multi-center, observational study to explore the relationship between exploratory biomarkers and functional dimensions in adults with autistic spectrum disorders. European Neuropsychopharmacology. 26. S193–S193. 2 indexed citations

14.

Li, Daniel H., Rémi J. Creusot, Shalina S. Ousman, et al.. (2007). Suppressive Role of CD72 in Experimental Autoimmune Encephalomyelitis (128.22). The Journal of Immunology. 178(1_Supplement). S214–S214. 1 indexed citations

15.

Platten, Michael, Peggy P. Ho, Sawsan Youssef, et al.. (2005). Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite. Science. 310(5749). 850–855. 350 indexed citations

16.

Ho, Peggy P., Paulo Fontoura, Michael Platten, et al.. (2005). A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease. The Journal of Immunology. 175(9). 6226–6234. 47 indexed citations

17.

Fontoura, Paulo, Peggy P. Ho, Jason DeVoss, et al.. (2004). Immunity to the Extracellular Domain of Nogo-A Modulates Experimental Autoimmune Encephalomyelitis. The Journal of Immunology. 173(11). 6981–6992. 51 indexed citations

18.

Ho, Peggy P., Paulo Fontoura, Pedro Ruiz, Lawrence Steinman, & Hideki Garren. (2003). An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems. The Journal of Immunology. 171(9). 4920–4926. 69 indexed citations

19.

Ruiz, Pedro, Jason DeVoss, Paulo Fontoura, et al.. (2001). Immunomodulation of Experimental Autoimmune Encephalomyelitis with Ordered Peptides Based on MHC-TCR Binding Motifs. The Journal of Immunology. 167(5). 2688–2693. 13 indexed citations

20.

Fontoura, Paulo, et al.. (2000). Pseudotumor cerebral: el lado maligno del espectro clínico. Revista Ecuatoriana de Neurologia. 9(3). 61–64. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact